Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. - Wikidata - awgldk - TriplyDB

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.

http://www.wikidata.org/entity/Q46251291

about

Update on treatment of light chain amyloidosis Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.Light-chain amyloidosis: SCT, novel agents and beyond.Light chain amyloidosis 2012: a new era.New insights and modern treatment of AL amyloidosis.Immunoglobulin light chain amyloidosis.Pathophysiology and treatment of cardiac amyloidosis.Recent advances in the management of AL Amyloidosis.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.New and developing therapies for AL amyloidosis.Systemic amyloidosis: novel therapies and role of biomarkers.Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy.Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.Hereditary Fibrinogen Aα-Chain Amyloidosis in Asia: Clinical and Molecular Characteristics.Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation.Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients

P2860

Q26829735-1681F5A0-92A0-4820-9312-D8C5CC495523 Q30278687-7FA8DB31-3580-44BC-9E19-108F3A50D679 Q34448455-0B94984B-4BAC-47C6-9680-A2ADA2EFD306 Q35081363-DB851913-9901-40A3-998F-F725A24AFC81 Q37570615-E7654567-5C64-4FAF-BE84-901B5608FFED Q38056010-6D354180-7F84-4CA3-8A98-6CE5B3CE2B1F Q38072108-49E91376-4FCF-462B-8FF9-F1053DDA414E Q38136576-09B3A1E9-BC91-4C43-876E-6ABC6CAADD56 Q38172295-2F96A4BC-4E2B-442B-A701-E222662A14AB Q38259728-6A27F87A-AF7C-4FB1-B52E-026F457882F1 Q38613822-E73CFB8C-717E-4274-BD5A-79B1D243A687 Q38614967-59C3BDBD-F0AB-4CD5-BC7D-6A3643CE8F14 Q38779623-69CE0D8D-1D40-4FBB-85C6-B85BFFD98509 Q38829923-1724E3EC-5D5E-4321-9368-8573EB3CF831 Q38928383-0AE63DE8-0075-4301-BD79-E944E45A465B Q38959241-D9B75439-2B08-44DD-A3E6-C8921A34C914 Q39217713-72A4E251-6075-42E8-8737-569808E9FF8A Q41021929-1CCD381D-EFBA-4D88-BC4A-1CB53ACCED1E Q46048669-E084CCA7-74E5-4806-AEF4-49BEBF1FE7E2 Q48156924-4D24869B-5533-4D9B-B988-9E6F781D4B8C Q48182611-64B73BDA-8726-433E-B5EF-5A5D77EDFCD9 Q51683327-805D641D-B074-4FC7-A594-3061C6B48CAC Q55023498-D7532C9C-CF65-4FE0-BBF8-CCA38FA37039 Q58029880-9683AAF1-ACD9-463B-AE93-FE7FA0A3C71C

P2860

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.

http://www.wikidata.org/entity/Q46251291

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Bortezomib and dexamethasone c ...... nosed light-chain amyloidosis.

@en

Bortezomib and dexamethasone c ...... nosed light-chain amyloidosis.

@nl

type

label

Bortezomib and dexamethasone c ...... nosed light-chain amyloidosis.

@en

Bortezomib and dexamethasone c ...... nosed light-chain amyloidosis.

@nl

prefLabel

Bortezomib and dexamethasone c ...... nosed light-chain amyloidosis.

@en

Bortezomib and dexamethasone c ...... nosed light-chain amyloidosis.

@nl

P1433

Q46251291-96F2B10B-23AE-4469-945C-12DDE36E8EF4

P1476

Q46251291-CFA8A3FD-70DC-4BD0-BC41-524BB13FF4F4

P2093

Q46251291-0CE43A8C-BDB5-449C-A912-AE2D57FA8FC6

Q46251291-23587503-D742-4D45-938F-DE938DAAC8D9

Q46251291-636BB602-F509-4536-80DA-0B4F2A58ADAF

Q46251291-84B35C81-8E50-425C-B153-974473830C14

Q46251291-8E4E7E8F-5D68-4000-AF7B-D9F812B8EDDA

Q46251291-A464B037-0EDD-4DFB-8E53-5AE8C0BCA255

Q46251291-B10BDBDF-D6CD-4ABE-8B35-F53A51DBB50F

Q46251291-DF736E20-B2D9-4473-BDE6-3419CD1BF167

Q46251291-E010285A-3824-4A00-9967-0DADCE519CD4

Q46251291-F88DA674-B2FD-4C64-BBF9-D169DAD6FC5F

P2860

Q46251291-0FA85937-BCA2-42C9-9750-47B18383EAA9

Q46251291-11424410-BF19-4F6D-816E-F154FE315C57

Q46251291-1ECA8BF0-65DB-420F-945F-6D7BAA2362DE

Q46251291-2F220142-802C-4C6F-B9A2-3CE909075778

Q46251291-39C14BE5-22BF-44F8-A440-C27913FE3838

Q46251291-44892096-3F07-449F-A6EE-B689620A4E4E

Q46251291-4B680062-8CE1-4ED2-AC46-E419E99E72BB

Q46251291-52002133-EEC0-4431-9A39-E2E6306B35AC

Q46251291-5C0FE69E-DBE4-4565-9A3D-4D8D0C2732DE

Q46251291-6A0B202E-E290-40D1-818A-30CED4199BAF

P2888

Q46251291-A2191C2B-7F6A-480E-A547-C024E9E3B2A7

P304

Q46251291-D5E2C31E-892A-485C-B1B7-99D809CC5FCE

P31

Q46251291-C400629D-5655-4EB4-95E5-F1F803BF1378

P356

Q46251291-7078379D-B459-4FE8-9845-3A46D1F865CF

P433

Q46251291-3EB589CA-F6B5-4B96-BE8A-9E32BC71CF3E

P478

Q46251291-4851D785-CDF9-4582-BA0F-50EFC83ACBCF

P577

Q46251291-30465167-B407-4338-B775-75B0CAA2EDBE

P698

Q46251291-5A24A6CD-8C66-441C-ABCC-66DFA11D798E

P921

Q46251291-30CDDB25-8344-476E-B43D-EA5632743849

P356

P1433

P1476

Bortezomib and dexamethasone c ...... nosed light-chain amyloidosis.

@en

P2093

C Bello

http://www.w3.org/2001/XMLSchema#string

C Flombaum

http://www.w3.org/2001/XMLSchema#string

E Hoover

http://www.w3.org/2001/XMLSchema#string

E Riedel

http://www.w3.org/2001/XMLSchema#string

H Hassoun

http://www.w3.org/2001/XMLSchema#string

H Landau

http://www.w3.org/2001/XMLSchema#string

J Liu

http://www.w3.org/2001/XMLSchema#string

M A Rosenzweig

http://www.w3.org/2001/XMLSchema#string

M Maurer

http://www.w3.org/2001/XMLSchema#string

R L Comenzo

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy.

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Autologous stem cell transplantation for primary systemic amyloidosis.

Molecular mechanisms of amyloidosis.

Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies.

Antibody-mediated resolution of light chain-associated amyloid deposits.

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

P2888

P304

823-828

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2012.274

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23014566

http://www.w3.org/2001/XMLSchema#string

P921